Detection of prostate cancer with 18F-DCFPyL PET/CT compared to final histopathology of radical prostatectomy specimens: is PSMA-targeted biopsy feasible? The DeTeCT trial - Top-Institutions - MDSpire

Detection of prostate cancer with 18F-DCFPyL PET/CT compared to final histopathology of radical prostatectomy specimens: is PSMA-targeted biopsy feasible? The DeTeCT trial

  • By

  • Y. J. L. Bodar

  • B. H. E. Jansen

  • J. P. van der Voorn

  • G. J. C. Zwezerijnen

  • D. Meijer

  • J. A. Nieuwenhuijzen

  • R. Boellaard

  • N. H. Hendrikse

  • O. S. Hoekstra

  • R. J. A. van Moorselaar

  • D. E. Oprea-Lager

  • A. N. Vis

  • October 20, 2020

  • 0 min

Share

Top Institutions in Urology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Urologic Oncology
    • Nuclear Medicine
    • Radiology

  • #2

    University of California, Los Angeles (UCLA) Medical Center
    University of California, Los Angeles (UCLA) Medical Center

    Los Angeles, CA

    Key Differentiators

    • Urologic Oncology
    • Nuclear Medicine
    • Radiology

  • #3

    Amsterdam University Medical Centers (Amsterdam UMC), Location VUmc
    Amsterdam University Medical Centers (Amsterdam UMC), Location VUmc

    Amsterdam, North Holland

    Key Differentiators

    • Urologic Oncology
    • Nuclear Medicine
    • Pathology

  • #4

    University of Michigan Rogel Cancer Center
    University of Michigan Rogel Cancer Center

    Ann Arbor, MI

    Key Differentiators

    • Urologic Oncology
    • Nuclear Medicine
    • Radiology

  • #5

    Johns Hopkins Hospital
    Johns Hopkins Hospital

    Baltimore, MD

    Key Differentiators

    • Urologic Oncology
    • Nuclear Medicine
    • Pathology

Original Source(s)

Detection of prostate cancer with 18F-DCFPyL PET/CT compared to final histopathology of radical prostatectomy specimens: is PSMA-targeted biopsy feasible? The DeTeCT trial

  • by Y. J. L. Bodar, B. H. E. Jansen, J. P. van der Voorn, G. J. C. Zwezerijnen, D. Meijer, J. A. Nieuwenhuijzen, R. Boellaard, N. H. Hendrikse, O. S. Hoekstra, R. J. A. van Moorselaar, D. E. Oprea-Lager, A. N. Vis

  • October 20, 2020

Related Content

Pan-segmental intraprostatic lesions involving mid-gland and apex of prostate (mid-apical lesions): assessing the true value of extreme apical biopsy cores

Diagnostics and prognostic evaluation in renal cell tumors: the German S3 guidelines recommendations

Utilization of multiparametric prostate magnetic resonance imaging in clinical practice and focal therapy: report from a Delphi consensus project